Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioterrorism bill

This article was originally published in The Tan Sheet

Executive Summary

Public Health Security & Bioterrorism Preparedness & Response Act signed into law by President Bush June 12. Legislation establishes guidelines for stockpiling potassium iodide tablets, contains provisions to protect safety of food, drug supply. Law also reauthorizes Prescription Drug User Fee Act (1"The Tan Sheet" May 27, 2002, p. 18)...

You may also be interested in...



China: No Longer A Great Wall For Supplement Makers

Changes in export and import trade laws in China beginning next year could result in increased investment opportunity for U.S. dietary supplement manufacturers, according to industry stakeholder David Turner

Bioterror Defense May Be Hampered By Legal “Gaps,” FDLI Told

"Significant gaps" in the legal structure addressing bioterrorism remain in the areas of food and dietary supplements, despite broad food security initiatives by FDA and the White House, one biodefense specialist pointed out at the Food & Drug Law Institute conference on bioterrorism in Washington, D.C. Sept. 29

Potassium Iodide Stockpiling Guidelines Called For In Bioterrorism Bill

Within a year of enacting bioterrorism legislation, the Bush Administration will consult with federal, state and local agencies to establish guidelines for the stockpiling of potassium iodide (KI) tablets

Related Content

Topics

UsernamePublicRestriction

Register

PS094139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel